Regulators Can’t Decide About Crypto

transatlantic antitrust dance A review of an $8 billion deal between life sciences companies Illumina and Grail could signal a new playbook for antitrust enforcement. Regulators are trying to thwart the merger in the US and Europe, a trans-Atlantic coordination that unlocks resources to question more deals, as political pressure builds to investigate whether companies, …